ArticleCell death & disease2026
Chidamide induces ROS-driven ZAKα-dependent ribotoxic stress in endometrial cancer and enhances radiosensitivity in vitro and in vivo.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Chidamide is a selective histone deacetylase inhibitor with antitumor activity in several malignancies, but its mechanism of action in endometrial cancer (EC) remains poorly understood. In this study, we investigated the cytotoxic effects and underlying mechanism of chidamide in EC using cell lines, patient-derived organoids (PDOs), cell-derived xenograft (CDX) models, and patient-derived xenograft (PDX) models. Chidamide markedly inhibited EC cell growth and induced reactive oxygen species (ROS) accumulation, DNA damage, G2/M-phase arrest, and apoptosis. Mechanistically, transcriptomic and functional analyses showed that chidamide disrupted translational homeostasis and activated a ROS-dependent, ZAKα-mediated ribotoxic stress response, leading to p38 and JNK activation. Scavenging ROS with N-acetylcysteine (NAC) attenuated ZAKα-MAPK signaling, and partially rescued chidamide-induced cell cycle arrest and apoptosis. Similarly, pharmacological ZAK inhibition or ZAKα silencing weakened stress signaling and diminished the cytotoxic effects of chidamide, supporting the central role of the ROS-ZAKα-MAPK axis. Chidamide also activated the GCN2-eIF2α-ATF4 integrated stress response, and ISRIB further enhanced stress signaling and apoptosis, suggesting an adaptive buffering role of this pathway. In addition to its activity in vitro, chidamide showed broad antitumor efficacy in PDO, CDX, and PDX models. Chidamide also enhanced tumor radiosensitivity in vivo, supporting its potential utility in combination with radiotherapy. Together, these findings identify ROS-driven, ZAKα-dependent ribotoxic stress signaling as a key mechanism underlying chidamide-induced cytotoxicity in EC and provide a mechanistic rationale for the further development of chidamide-based strategies in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.